Stock events for Zymeworks, Inc. (ZYME)
Over the past six months, Zymeworks' stock has increased significantly. Key events include a weak Q4 2025 earnings report, a $250 million royalty-backed financing, positive clinical and regulatory milestones for Zanidatamab, insider trading activity, and participation in investor conferences.
Demand Seasonality affecting Zymeworks, Inc.’s stock price
The demand for Zymeworks' products and services is primarily driven by medical need, clinical trial progress, and regulatory approvals, rather than seasonal patterns. No specific information indicating demand seasonality for Zymeworks, Inc.'s products or services was found.
Overview of Zymeworks, Inc.’s business
Zymeworks, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation multifunctional biotherapeutics. The company operates in the Healthcare sector, specializing in engineered antibody and protein therapeutics for unmet medical needs, particularly in oncology and other serious diseases. Zymeworks' innovation lies in its proprietary platforms, including Azymetric™, Torque™, Engine™, Armory™, EFECT, and ProTECT. Key product candidates include Zanidatamab (Ziihera®), Zanidatamab Zovodotin (ZW49), Pasritamig, ZW191, ZW209 and ZW1528. The company has strategic partnerships with global biopharmaceutical companies and is evolving into a royalty-driven organization.
ZYME’s Geographic footprint
Zymeworks is headquartered in Middletown, Delaware, with a corporate office in Vancouver, Canada, and R&D facilities in both countries. The company has a global presence through strategic alliances and clinical trials, with potential commercialization efforts extending to the U.S., Europe, Japan, and China.
ZYME Corporate Image Assessment
Zymeworks generally holds a positive brand reputation, particularly among analysts, with a consensus rating of "Moderate Buy". The company is recognized for its innovative therapeutic platforms, strategic partnerships, and shift to a royalty-driven business model. The company's financial health is characterized by significant losses since its inception, a common challenge in the biopharmaceutical industry.
Ownership
Zymeworks Inc. has significant institutional and insider ownership. Major institutional owners include EcoR1 Capital, LLC, Rubric Capital Management LP, and BlackRock, Inc. Major individual owners and insiders include Ecor1 Capital LLC, Oleg Nodelman, and Kenneth Galbraith.
